| Identification | Back Directory | [Name]
PHCCC | [CAS]
179068-02-1 | [Synonyms]
PHCCC >=97% (HPLC)
7,7a-Dihydro-7-(hydroxyimino)-N-phenylbenzo[b]cyclopropa[e]pyran-1a(1H)-carboxamide
Benzo[b]cyclopropa[e]pyran-1a(1H)-carboxamide, 7,7a-dihydro-7-(hydroxyimino)-N-phenyl- | [Molecular Formula]
C17H14N2O3 | [MOL File]
179068-02-1.mol | [Molecular Weight]
294.3 |
| Chemical Properties | Back Directory | [storage temp. ]
Inert atmosphere,2-8°C | [solubility ]
Soluble in DMSO | [form ]
Powder | [color ]
White to off-white | [InChI]
1S/C17H14N2O3/c20-16(18-11-6-2-1-3-7-11)17-10-13(17)15(19-21)12-8-4-5-9-14(12)22-17/h1-9,13,21H,10H2,(H,18,20)/b19-15+ | [InChIKey]
FPXPIEZPAXSELW-XDJHFCHBSA-N | [SMILES]
O=C(NC1=CC=CC=C1)C2(C/3C2)OC4=C(C=CC=C4)C3=N/O |
| Hazard Information | Back Directory | [Uses]
PHCCC is a Group I mGluR antagonist with an IC50 of 3 μM. PHCCC is a selective positive modulator of mGlu4 receptor. Antiparkinsonian effect[1][2]. | [Definition]
ChEBI: 7-hydroxyimino-N-phenyl-1,7a-dihydrocyclopropa[b][1]benzopyran-1a-carboxamide is a 1-benzopyran. | [Biological Activity]
PHCCC is a positive allosteric modulator (PAM) at the mGluR4 subtype th at exhibits anxiolytic and anti-Parkinsonian effects in animal models. PHCCC is a potent group I metabotropic glutamate receptor antagonist. | [in vivo]
PHCCC (75 nmol/2.5 μl; intracerebroventricular) produces an antiparkinsonian effect in a dopamine depletion akinesia model[2]. | [IC 50]
Group I mGluR receptors: 3 μM (IC50) | [storage]
Store at RT | [References]
[1] Récasens M, et al. Metabotropic glutamate receptors as drug targets. Curr Drug Targets. 2007;8(5):651-681. DOI:10.2174/138945007780618544
[2] Marino MJ et al. Allosteric modulation of group III metabotropic glutamate receptor 4: a potential approach to Parkinson's disease treatment. Proc Natl Acad Sci U S A. 2003 Nov 11;100(23):13668-73. DOI:10.1073/pnas.1835724100 |
|
| Company Name: |
Musechem
|
| Tel: |
+1-800-259-7612 |
| Website: |
www.musechem.com |
|